Deficient arsenic methylation and global proteomic reprogramming in human keratinocytes during arsenic-induced skin carcinogenesis - Scorecard - MDSpire

Deficient arsenic methylation and global proteomic reprogramming in human keratinocytes during arsenic-induced skin carcinogenesis

  • By

  • Alexandra N. Nail

  • Mayukh Banerjee

  • Manting Xu

  • Caitlin H. Reynolds

  • Miroslav Stýblo

  • Peter H. Cable

  • Daniel W. Wilkey

  • Michael L. Merchant

  • Ana P. Ferragut Cardoso

  • Shelia D. Thomas

  • J. Christopher States

  • June 27, 2026

  • 0 min

Share

Clinical Scorecard: Impaired Arsenic Methylation and Comprehensive Proteomic Alterations in Human Keratinocytes During Skin Cancer Development Induced by Arsenic

At a Glance

CategoryDetail
ConditionSkin Cancer
Key MechanismsChronic exposure to inorganic arsenic leads to malignant transformation of human keratinocytes.
Target PopulationIndividuals exposed to inorganic arsenic in drinking water.
Care SettingPreclinical research and molecular biology studies.

Key Highlights

  • Chronic exposure to inorganic arsenic is linked to non-melanoma skin cancer.
  • HaCaT cells serve as a model for studying arsenic-induced cutaneous squamous cell carcinoma.
  • Differential protein expression changes occur during arsenic-induced malignant transformation.
  • Arsenic methylation status may influence carcinogenic outcomes in keratinocytes.
  • Longitudinal proteomic profiling is essential for understanding the mechanisms of arsenic-induced carcinogenesis.

Guideline-Based Recommendations

Diagnosis

  • Monitor for skin cancer in populations with known arsenic exposure.

Management

  • Implement strategies to reduce arsenic exposure in drinking water.

Monitoring & Follow-up

  • Conduct regular skin examinations for early detection of skin cancer.

Risks

  • Increased risk of skin cancer associated with chronic arsenic exposure.

Patient & Prescribing Data

Individuals with chronic arsenic exposure.

Understanding the molecular pathways may inform targeted therapies for arsenic-induced skin cancer.

Clinical Best Practices

  • Utilize preclinical models to study the effects of arsenic on skin carcinogenesis.
  • Assess arsenic methylation status in keratinocyte studies.

Related Resources & Content

Original Source(s)

Related Content